Tumors hamper the immunogenic competence of CD4 + T cell-directed dendritic cell vaccination

Valérie S. Zimmermann, Anna Casati, Chris Schiering, Stefano Caserta, Rodrigo Hess Michelini, Veronica Basso, Anna Mondino

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Dendritic cells loaded with tumor-derived peptides induce protective CTL responses and are under evaluation in clinical trails. We report in this study that prophylactic administration of dendritic cells loaded with a MHC class II-restricted peptide derived from a model tumor Ag (Leishmania receptor for activated C kinase (LACK)) confers protection against LACK-expressing TS/A tumors, whereas therapeutic vaccination fails to cure tumor-bearing mice. Although CD4 + T cell-directed dendritic cell vaccination primed effector-like (CD44 highCD62L low, IL-2 +, IFN-γ +) and central memory-like lymphocytes (CD44 highCD62L high, only IL-2 +) in tumor-free mice, this was not the case in tumor-bearing animals in which both priming and persistence of CD4 + T cell memory were suppressed. Suppression was specific for the tumor-associated Ag LACK, and did not depend on CD25 + T cells. Because T cell help is needed for protective immunity, we speculate that the ability of tumors to limit vaccine-induced CD4 + T cell memory could provide a partial explanation for the limited efficacy of current strategies.

Original languageEnglish
Pages (from-to)2899-2909
Number of pages11
JournalJournal of Immunology
Volume179
Issue number5
Publication statusPublished - Sep 1 2007

Fingerprint

Mental Competency
Dendritic Cells
Vaccination
T-Lymphocytes
Leishmania
Neoplasms
Interleukin-2
Peptides
Aptitude
Immunity
Vaccines
Lymphocytes
receptors for activated C kinase

ASJC Scopus subject areas

  • Immunology

Cite this

Zimmermann, V. S., Casati, A., Schiering, C., Caserta, S., Michelini, R. H., Basso, V., & Mondino, A. (2007). Tumors hamper the immunogenic competence of CD4 + T cell-directed dendritic cell vaccination. Journal of Immunology, 179(5), 2899-2909.

Tumors hamper the immunogenic competence of CD4 + T cell-directed dendritic cell vaccination. / Zimmermann, Valérie S.; Casati, Anna; Schiering, Chris; Caserta, Stefano; Michelini, Rodrigo Hess; Basso, Veronica; Mondino, Anna.

In: Journal of Immunology, Vol. 179, No. 5, 01.09.2007, p. 2899-2909.

Research output: Contribution to journalArticle

Zimmermann, VS, Casati, A, Schiering, C, Caserta, S, Michelini, RH, Basso, V & Mondino, A 2007, 'Tumors hamper the immunogenic competence of CD4 + T cell-directed dendritic cell vaccination', Journal of Immunology, vol. 179, no. 5, pp. 2899-2909.
Zimmermann VS, Casati A, Schiering C, Caserta S, Michelini RH, Basso V et al. Tumors hamper the immunogenic competence of CD4 + T cell-directed dendritic cell vaccination. Journal of Immunology. 2007 Sep 1;179(5):2899-2909.
Zimmermann, Valérie S. ; Casati, Anna ; Schiering, Chris ; Caserta, Stefano ; Michelini, Rodrigo Hess ; Basso, Veronica ; Mondino, Anna. / Tumors hamper the immunogenic competence of CD4 + T cell-directed dendritic cell vaccination. In: Journal of Immunology. 2007 ; Vol. 179, No. 5. pp. 2899-2909.
@article{4404f6587a7b41a5895551116bc0f00d,
title = "Tumors hamper the immunogenic competence of CD4 + T cell-directed dendritic cell vaccination",
abstract = "Dendritic cells loaded with tumor-derived peptides induce protective CTL responses and are under evaluation in clinical trails. We report in this study that prophylactic administration of dendritic cells loaded with a MHC class II-restricted peptide derived from a model tumor Ag (Leishmania receptor for activated C kinase (LACK)) confers protection against LACK-expressing TS/A tumors, whereas therapeutic vaccination fails to cure tumor-bearing mice. Although CD4 + T cell-directed dendritic cell vaccination primed effector-like (CD44 highCD62L low, IL-2 +, IFN-γ +) and central memory-like lymphocytes (CD44 highCD62L high, only IL-2 +) in tumor-free mice, this was not the case in tumor-bearing animals in which both priming and persistence of CD4 + T cell memory were suppressed. Suppression was specific for the tumor-associated Ag LACK, and did not depend on CD25 + T cells. Because T cell help is needed for protective immunity, we speculate that the ability of tumors to limit vaccine-induced CD4 + T cell memory could provide a partial explanation for the limited efficacy of current strategies.",
author = "Zimmermann, {Val{\'e}rie S.} and Anna Casati and Chris Schiering and Stefano Caserta and Michelini, {Rodrigo Hess} and Veronica Basso and Anna Mondino",
year = "2007",
month = "9",
day = "1",
language = "English",
volume = "179",
pages = "2899--2909",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Tumors hamper the immunogenic competence of CD4 + T cell-directed dendritic cell vaccination

AU - Zimmermann, Valérie S.

AU - Casati, Anna

AU - Schiering, Chris

AU - Caserta, Stefano

AU - Michelini, Rodrigo Hess

AU - Basso, Veronica

AU - Mondino, Anna

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Dendritic cells loaded with tumor-derived peptides induce protective CTL responses and are under evaluation in clinical trails. We report in this study that prophylactic administration of dendritic cells loaded with a MHC class II-restricted peptide derived from a model tumor Ag (Leishmania receptor for activated C kinase (LACK)) confers protection against LACK-expressing TS/A tumors, whereas therapeutic vaccination fails to cure tumor-bearing mice. Although CD4 + T cell-directed dendritic cell vaccination primed effector-like (CD44 highCD62L low, IL-2 +, IFN-γ +) and central memory-like lymphocytes (CD44 highCD62L high, only IL-2 +) in tumor-free mice, this was not the case in tumor-bearing animals in which both priming and persistence of CD4 + T cell memory were suppressed. Suppression was specific for the tumor-associated Ag LACK, and did not depend on CD25 + T cells. Because T cell help is needed for protective immunity, we speculate that the ability of tumors to limit vaccine-induced CD4 + T cell memory could provide a partial explanation for the limited efficacy of current strategies.

AB - Dendritic cells loaded with tumor-derived peptides induce protective CTL responses and are under evaluation in clinical trails. We report in this study that prophylactic administration of dendritic cells loaded with a MHC class II-restricted peptide derived from a model tumor Ag (Leishmania receptor for activated C kinase (LACK)) confers protection against LACK-expressing TS/A tumors, whereas therapeutic vaccination fails to cure tumor-bearing mice. Although CD4 + T cell-directed dendritic cell vaccination primed effector-like (CD44 highCD62L low, IL-2 +, IFN-γ +) and central memory-like lymphocytes (CD44 highCD62L high, only IL-2 +) in tumor-free mice, this was not the case in tumor-bearing animals in which both priming and persistence of CD4 + T cell memory were suppressed. Suppression was specific for the tumor-associated Ag LACK, and did not depend on CD25 + T cells. Because T cell help is needed for protective immunity, we speculate that the ability of tumors to limit vaccine-induced CD4 + T cell memory could provide a partial explanation for the limited efficacy of current strategies.

UR - http://www.scopus.com/inward/record.url?scp=38449094324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449094324&partnerID=8YFLogxK

M3 - Article

C2 - 17709504

AN - SCOPUS:38449094324

VL - 179

SP - 2899

EP - 2909

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -